This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.


This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?

Steno Diabetes Center Copenhagen, University of Copenhagen, Denmark

Professor Vilsbøll has been involved in diabetes research since 1997, and in 2004 she established the Center for Diabetes Research at Gentofte Hospital, University of Copenhagen, Denmark now part of Steno Diabetes Center Copenhagen. Her research is focused on the pathophysiology of obesity, prediabetes, type 2 diabetes, regulation of appetite and food intake, and the utilisation of incretins as therapeutics. Integration of the gut in the understanding of human glucose metabolism has become a major focus in her lab over recent years. Professor Vilsbøll is an experienced teacher and supervises several PhD and medical students conducting diabetes research. She has more than 370 scientific publications (H-index 74), several published books and book chapters. She is a frequently invited speaker at international meetings. In addition to her teaching and research posts, Professor Vilsbøll is a member of numerous professional societies and committees, and referees for several international journals.

Subodh Verma

Subodh Verma

University of Toronto, Toronto, USA

Dr Subodh Verma is an internationally renowned cardiac surgeon-scientist and Professor at the University of Toronto. He is the current Canada Research Chair in Cardiovascular Surgery, having previously served as the Canada Research Chair in Atherosclerosis (2007-2017). Dr Verma was awarded the Lister Prize in Surgery from the University of Toronto in 2021 in recognition of his outstanding and continuing productivity of international stature. He is a past recipient of the Howard Morgan Award for Distinguished Achievements in Cardiovascular Research from the International Academy of Cardiovascular Sciences and the Royal College of Physicians and Surgeons of Canada Gold Medal in Surgery. Dr Verma is an appointee of the American Association of Thoracic Surgeons (AATS) and a member of the Royal Society of Canada College of New Scholars, Artists and Scientists.

Dr Verma’s over 500 peer-reviewed publications have earned him a Google Scholar h-index of 108 with ~58,000 citations. He has published extensively in highly impactful journals like the NEJM, Lancet, Nature, Circulation, European Heart Journal and JACC. He is an Associate Editor of the European Heart Journal. Dr Verma is an active contributor to Canadian clinical practice guidelines and co-authored the recently updated recommendations for atrial fibrillation, antiplatelet therapy, diabetes, and heart failure; he was also a member of the 2018 AATS consensus guidelines committee on bicuspid aortic valverelated aortopathy. Dr Verma has served in various capacities on the American Heart Association Council on Cardiovascular Surgery and Anesthesia since 2008.

Dr Verma had/has leadership roles in multiple contemporary global heart failure trials – several of which persuaded guideline writing committees to recommend paradigm changes in how individuals who live with heart failure should be managed. He founded the CardioLink platform at St Michael’s Hospital that united cardiac surgeons from across Canada to conduct robust clinical trials to better inform on surgical decision-making pathways. CardioLink has since expanded its scope to include cardiometabolic studies.

Dr Verma leads a dynamic pre-clinical and translational research team that leverages pre-clinical disease models and clinical trial-derived data to identify novel mediators of cardiometabolic diseases. His current research is centred around modulating vascular regenerative cell exhaustion to alleviate cardiometabolic risk. Dr Verma holds 2 United States patents, and his research program is supported by national peer-reviewed grants.

Read full bio